| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/27/2011 | US20110021504 Polymorphic form d of bazedoxifene acetate and methods of preparing same |
| 01/27/2011 | US20110021498 Indolyl- pyridone derivatives having checkpoint kinase 1 inhibitory activity |
| 01/27/2011 | US20110021497 Amino triazoles as pi3k inhibitors |
| 01/27/2011 | US20110021494 Novel tetrahydro-fused pyridines as histone deacetylase inhibitors |
| 01/27/2011 | US20110021493 Substituted tricyclic compounds and methods of use thereof |
| 01/27/2011 | US20110021485 Indole derivatives and their metal conjugates and uses thereof |
| 01/27/2011 | US20110021483 Platinum (IV) Complexes |
| 01/27/2011 | US20110021481 Novel Compounds and Methods for Their Production |
| 01/27/2011 | US20110021480 17-beta HSD1 and STS Inhibitors |
| 01/27/2011 | US20110021475 Compositions And Methods for Treatment Of Fibrosis |
| 01/27/2011 | US20110021470 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same |
| 01/27/2011 | US20110021462 Substituted tetrahydro-2h-isoquinolin-1-one derivatives, and methods for the production and use thereof |
| 01/27/2011 | US20110021452 Lyophilized preparation of stabilized anthracycline compounds |
| 01/27/2011 | US20110021451 Lipid tumour profile |
| 01/27/2011 | US20110021449 Macrolides and uses of macrolides |
| 01/27/2011 | US20110021442 Cell preamble runx3 recombinant proteins, polynucleotides encoding the same, and anticancer compositions including the same |
| 01/27/2011 | US20110021440 Apoptotic pathway targeting for the diagnosis and treatment of cancer |
| 01/27/2011 | US20110021434 Macrocyclic Cysteine Protease Inhibitors and Compositions Thereof |
| 01/27/2011 | US20110021424 Polypeptide derived from protein a and able to bind pdgf |
| 01/27/2011 | US20110021419 Methods and Compositions for the Treatment of Heart Failure and Other Disorders |
| 01/27/2011 | US20110020951 Purified sr-p70 protein |
| 01/27/2011 | US20110020901 Methods of Making Viral Particles Having a Modified Cell Binding Activity and Uses Thereof |
| 01/27/2011 | US20110020480 Use of benzoxazinoids-containing cereal grain products for health-improving purposes |
| 01/27/2011 | US20110020479 Methods for modulating eicosanoid metabolism |
| 01/27/2011 | US20110020470 Methods and compositions for treating cancer |
| 01/27/2011 | US20110020469 Aminopyrimidines useful as kinase inhibitors |
| 01/27/2011 | US20110020457 Polymer-surfactant nanoparticles for sustained release of compounds |
| 01/27/2011 | US20110020441 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis |
| 01/27/2011 | US20110020437 Oligopeptidic compounds and uses thereof |
| 01/27/2011 | US20110020434 Nanoparticle arsenic-platinum compositions |
| 01/27/2011 | US20110020433 Compositions for delivery of cargo such as drugs proteins and/or genetic materials |
| 01/27/2011 | US20110020431 Antitumor effect of mutant bik |
| 01/27/2011 | US20110020430 Novel mRNA splice variant of the doublecortin-like kinase gene and its use in cancer diagnosis and therapy |
| 01/27/2011 | US20110020429 Use of particles comprising an alcohol |
| 01/27/2011 | US20110020424 Use of the irritating principal oleocanthal in olive oil, as well as structurally and functionally similar compounds |
| 01/27/2011 | US20110020400 Probiotic bifidobacterium strains |
| 01/27/2011 | US20110020392 Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers |
| 01/27/2011 | US20110020375 Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use |
| 01/27/2011 | US20110020373 Ige directed dna vaccination |
| 01/27/2011 | US20110020371 Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery |
| 01/27/2011 | US20110020368 Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
| 01/27/2011 | US20110020365 Methods and Compositions for Identifying, Diagnosing, and Treating Neuroblastoma |
| 01/27/2011 | US20110020361 Human anti-mesothelin monoclonal antibodies |
| 01/27/2011 | US20110020360 Targeted binding agents directed to pdgrf-alpha and uses thereof |
| 01/27/2011 | US20110020353 Antibodies and related molecules that bind to 161p2f10b proteins |
| 01/27/2011 | US20110020352 Endogenous retroviruses up-regulated in prostate cancer |
| 01/27/2011 | US20110020349 Anti-factor xi monoclonal antibodies and methods of use thereof |
| 01/27/2011 | US20110020346 Anti-vegf antibodies |
| 01/27/2011 | US20110020344 Human monoclonal antibodies specific for cd22 |
| 01/27/2011 | US20110020343 Auristatin drug linker conjugates |
| 01/27/2011 | US20110020340 Antibody-light fusion products for cancer therapeutics |
| 01/27/2011 | US20110020338 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes |
| 01/27/2011 | US20110020335 Treatment of Cancers Expressing p95 ErbB2 |
| 01/27/2011 | US20110020334 Methods for treating and preventing brain tumors based on bone morphogenetic proteins |
| 01/27/2011 | US20110020333 Angiogenesis Pathway Gene Polymorphisms for Therapy Selection |
| 01/27/2011 | US20110020332 Prevention of tumors with monoclonal antibodies against neu |
| 01/27/2011 | US20110020331 N-glycosylated antibody |
| 01/27/2011 | US20110020330 Antibody inhibitors of gdf-8 and uses thereof |
| 01/27/2011 | US20110020329 Conjugates of anti-rg-1 antibodies |
| 01/27/2011 | US20110020328 Antibody formulations |
| 01/27/2011 | US20110020321 Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/27/2011 | US20110020319 Use of anti- sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents |
| 01/27/2011 | US20110020317 Breast tumour grading |
| 01/27/2011 | US20110020314 Identifying haematopoietic stem cells based on cell surface markers |
| 01/27/2011 | US20110020308 Expression of transgenic t cell receptors in lak-t cells |
| 01/27/2011 | US20110020296 Methods for treating diseases and increasing longevity |
| 01/27/2011 | US20110020288 Reoviruses Having Modified Sequences |
| 01/27/2011 | US20110020287 Parvovirus Cancer Therapy and Combination with Chemotherapy |
| 01/27/2011 | US20110020284 Probiotic bifidobacterium strains |
| 01/27/2011 | US20110020282 Recombinant newcastle disease virus |
| 01/27/2011 | US20110020274 Mobilization of hematopoietic stem cells |
| 01/27/2011 | US20110020273 Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| 01/27/2011 | US20110020267 Tweak receptor |
| 01/27/2011 | US20110020242 High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles |
| 01/27/2011 | US20110020234 Rna interference mediating small rna molecules |
| 01/27/2011 | US20110020232 Cancer treatment with gama-secretase inhibitors |
| 01/27/2011 | US20110020228 Targeted cellular selectivity of surface active molecules |
| 01/27/2011 | US20110020227 Polysaccharide-containing block copolmer particles and uses thereof |
| 01/27/2011 | US20110020224 Apparatus and method for preparing medicines containing radioactive substances |
| 01/27/2011 | US20110020223 Polypeptides having affinity for her2 |
| 01/27/2011 | US20110020222 Modified antibodies and methods of use |
| 01/27/2011 | US20110020221 Cancer stem cell expression patterns and compounds to target cancer stem cells |
| 01/27/2011 | US20110020219 Anti-human tenascin monoclonal antibody |
| 01/27/2011 | US20110020218 Novel anti cxcr4 antibodies and their use for the treatment of cancer |
| 01/27/2011 | US20110020217 Treatment of melanoma |
| 01/27/2011 | DE102009034553A1 Impfstoff zur Prävention von akuter lymphoblastischer Leukämie bei Kindern Vaccine for the prevention of acute lymphoblastic leukemia in children |
| 01/27/2011 | CA2775443A1 Methods of treating and preventing/reducing the likelihood of mesial temporal lobe epilepsy (tle) |
| 01/27/2011 | CA2768631A1 Combination therapies with ck2 modulators |
| 01/27/2011 | CA2768494A1 Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| 01/27/2011 | CA2768466A1 Hdac inhibitors and therapeutic methods using the same |
| 01/27/2011 | CA2768373A1 Heteroaryl benzamides, compositions and methods of use |
| 01/27/2011 | CA2768078A1 Selenoquinone-derived active organometallic complexes, methods for synthesizing same, and uses thereof |
| 01/27/2011 | CA2767772A1 Potent small molecule inhibitors of autophagy, and methods of use thereof |
| 01/27/2011 | CA2767463A1 Benzoquinolizinium salt derivatives as anticancer agents |
| 01/26/2011 | EP2278028A1 Method for diagnosing non-small cell lung cancers |
| 01/26/2011 | EP2278024A1 Epitope cluster from NY-ESO-1 for the induction of anti-tumor immunogenicity |
| 01/26/2011 | EP2278023A1 Epitope cluster from Melan-A/MART-1 for the induction of anti-tumor immunogenicity |
| 01/26/2011 | EP2278004A1 RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA) |
| 01/26/2011 | EP2277919A1 Treatment with anti-ERBB2 antibodies |
| 01/26/2011 | EP2277917A2 B7-H3L cell surface target and a family of antibodies recognizing that target |